drugset / Trial / NCT03996265
Bupropion to Reduce Cancer Related Fatigue in Cancer Survivors
Phase 3
Active not recruiting
422 enrolled
University of Rochester NCORP Research Base
National Cancer Institute (NCI) · collab
RandomizedParallel-groupDouble-blindSupportive care
Summary
This phase III trial studies how well bupropion works in reducing cancer related fatigue in cancer survivors. Cancer and its treatment can cause fatigue. Bupropion is a drug that is used to treat depression, as well as to help people quit smoking. It belongs to the family of drugs called antidepressants and works by increasing certain types of activity in the brain. Bupropion may reduce cancer-related fatigue by causing changes in inflammation and stress hormones.
Timeline
- Start
- 2019-06-27
- Primary completion
- 2026-05-30
- Completion
- 2026-08-05
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Bupropion | Small molecule | — | Oral |